Your browser doesn't support javascript.
Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time.
Gonzalez Lopez Ledesma, María M; Sanchez, Lautaro; Ojeda, Diego S; Oviedo Rouco, Santiago; Rossi, Andrés H; Varese, Augusto; Mazzitelli, Ignacio; Pascuale, Carla A; Miglietta, Esteban A; Rodríguez, Pamela E; Pallarés, Horacio M; Costa Navarro, Guadalupe S; Caramelo, Julio J; Rothlauf, Paul W; Liu, Zhuoming; Bloyet, Louis-Marie; Cornejo Pontelli, Marjorie; Rasetto, Natali B; Wenker, Shirley D; Ramis, Lila Y; Bialer, Magalí G; de Leone, María Jose; Hernando, C Esteban; Bianchimano, Luciana; Ríos, Antonella S; Treffinger Cienfuegos, María Soledad; Rodriguez García, Diana R; Longueira, Yesica; Laufer, Natalia; Alvarez, Diego; Ceballos, Ana; Ochoa, Valeria; Monzani, Cecilia; Turk, Gariela; Salvatori, Melina; Carradori, Jorge; Prost, Katherine; Rima, Alejandra; Varela, Claudia; Ercole, Regina; Toro, Rosana I; Gutierrez, Sebastian; Zubieta, Martín; Acuña, Dolores; Nabaes Jodar, Mercedes S; Torres, Carolina; Mojsiejczuk, Laura; Viegas, Mariana; Velazquez, Pilar; Testa, Clarisa.
  • Gonzalez Lopez Ledesma MM; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Sanchez L; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Ojeda DS; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Oviedo Rouco S; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Rossi AH; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Varese A; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina.
  • Mazzitelli I; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina.
  • Pascuale CA; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Miglietta EA; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Rodríguez PE; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Pallarés HM; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Costa Navarro GS; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Caramelo JJ; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Rothlauf PW; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Liu Z; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Bloyet LM; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Cornejo Pontelli M; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Rasetto NB; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Wenker SD; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Ramis LY; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Bialer MG; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • de Leone MJ; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Hernando CE; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Bianchimano L; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Ríos AS; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Treffinger Cienfuegos MS; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Rodriguez García DR; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
  • Longueira Y; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina.
  • Laufer N; Biobanco de Enfermedades Infecciosas (INBIRS-UBA-CONICET), Buenos Aires, Argentina.
  • Alvarez D; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina.
  • Ceballos A; Biobanco de Enfermedades Infecciosas (INBIRS-UBA-CONICET), Buenos Aires, Argentina.
  • Ochoa V; Instituto de Investigaciones Biotecnológicas, UNSAM-CONICET, Buenos Aires, Argentina.
  • Monzani C; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina.
  • Turk G; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina.
  • Salvatori M; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina.
  • Carradori J; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina.
  • Prost K; Biobanco de Enfermedades Infecciosas (INBIRS-UBA-CONICET), Buenos Aires, Argentina.
  • Rima A; Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS-CONICET), Buenos Aires, Argentina.
  • Varela C; Laboratorio Lemos S.R.L., Buenos Aires, Argentina.
  • Ercole R; Hospital Interzonal General de Agudos Dr Pedro Fiorito, Buenos Aires, Argentina.
  • Toro RI; Hospital Interzonal General de Agudos Evita, Buenos Aires, Argentina.
  • Gutierrez S; Hospital Interzonal General de Agudos Prof. Dr. Rodolfo Rossi, Buenos Aires, Argentina.
  • Zubieta M; Hospital Interzonal Especializado de Agudos y Crónicos San Juan de Dios, Buenos Aires, Argentina.
  • Acuña D; Hospital Interzonal General de Agudos San Roque, Buenos Aires, Argentina.
  • Nabaes Jodar MS; Hospital Interzonal General de Agudos San Martín, Buenos Aires, Argentina.
  • Torres C; Hospital de Alta Complejidad El Cruce "Nestor Kirchner," Buenos Aires, Argentina.
  • Mojsiejczuk L; Hospital General de Niños Dr. Ricardo Gutierrez e Instituto de Investigaciones en Bacteriología y Virología Molecular, Fac de Farmacia y Bioquímica, UBA, Buenos Aires, Argentina.
  • Viegas M; Hospital General de Niños Dr. Ricardo Gutierrez e Instituto de Investigaciones en Bacteriología y Virología Molecular, Fac de Farmacia y Bioquímica, UBA, Buenos Aires, Argentina.
  • Velazquez P; Hospital General de Niños Dr. Ricardo Gutierrez e Instituto de Investigaciones en Bacteriología y Virología Molecular, Fac de Farmacia y Bioquímica, UBA, Buenos Aires, Argentina.
  • Testa C; Hospital General de Niños Dr. Ricardo Gutierrez e Instituto de Investigaciones en Bacteriología y Virología Molecular, Fac de Farmacia y Bioquímica, UBA, Buenos Aires, Argentina.
mBio ; : e0344221, 2022 Jan 25.
Article in English | MEDLINE | ID: covidwho-1649813
ABSTRACT
Recent studies have shown a temporal increase in the neutralizing antibody potency and breadth to SARS-CoV-2 variants in coronavirus disease 2019 (COVID-19) convalescent individuals. Here, we examined longitudinal antibody responses and viral neutralizing capacity to the B.1 lineage virus (Wuhan related), to variants of concern (VOC; Alpha, Beta, Gamma, and Delta), and to a local variant of interest (VOI; Lambda) in volunteers receiving the Sputnik V vaccine in Argentina. Longitudinal serum samples (N = 536) collected from 118 volunteers obtained between January and October 2021 were used. The analysis indicates that while anti-spike IgG levels significantly wane over time, the neutralizing capacity for the Wuhan-related lineages of SARS-CoV-2 and VOC is maintained within 6 months of vaccination. In addition, an improved antibody cross-neutralizing ability for circulating variants of concern (Beta and Gamma) was observed over time postvaccination. The viral variants that displayed higher escape to neutralizing antibodies with respect to the original virus (Beta and Gamma variants) were the ones showing the largest increase in susceptibility to neutralization over time after vaccination. Our observations indicate that serum neutralizing antibodies are maintained for at least 6 months and show a reduction of VOC escape to neutralizing antibodies over time after vaccination. IMPORTANCE Vaccines have been produced in record time for SARS-CoV-2, offering the possibility of halting the global pandemic. However, inequalities in vaccine accessibility in different regions of the world create a need to increase international cooperation. Sputnik V is a recombinant adenovirus-based vaccine that has been widely used in Argentina and other developing countries, but limited information is available about its elicited immune responses. Here, we examined longitudinal antibody levels and viral neutralizing capacity elicited by Sputnik V vaccination. Using a cohort of 118 volunteers, we found that while anti-spike antibodies wane over time, the neutralizing capacity to viral variants of concern and local variants of interest is maintained within 4 months of vaccination. In addition, we observed an increased cross-neutralization activity over time for the Beta and Gamma variants. This study provides valuable information about the immune response generated by a vaccine platform used in many parts of the world.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Language: English Journal: MBio Year: 2022 Document Type: Article Affiliation country: Mbio.03442-21

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Language: English Journal: MBio Year: 2022 Document Type: Article Affiliation country: Mbio.03442-21